Oncology

News

AZ's CEO dismisses "fake news" about his imminent departure

AstraZeneca’s CEO Pascal Soriot has dismissed continued rumours about his departure as “fake news” as the company announced full year results showing sales growth for the first time in a de

News

Packaged Pills in aluminium blisters stacked on each other

Clinigen buys remaining rights to Novartis cancer drug

UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million.

News

AZ's chief medical officer Bohen quits after shake-up

AstraZeneca’s chief medical officer Sean Bohen is to leave the company following its organisational shake-up.

News

Lilly further boosts cancer pipeline with $8bn Loxo acquisit...

In the second big M&A deal of the year following BMS’s acquisition

News

Takeda strikes three new immuno-oncology deals

Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology.

Events

Partner Content

The Pharma Forecasting Workshop - Fundamentals of Forecastin...

J+D Interactive Pharma Forecasting Workshop

AZ's CEO dismisses "fake news" about his imminent departure

Clinigen buys remaining rights to Novartis cancer drug

AZ's chief medical officer Bohen quits after shake-up

Lilly further boosts cancer pipeline with $8bn Loxo acquisit...

Takeda strikes three new immuno-oncology deals

The Pharma Forecasting Workshop - Fundamentals of Forecastin...

Novo turns to Hengrui for another oral obesity drug

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks